To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Value of cerebrospinal fl… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Value of cerebrospinal fluid -synuclein species as biomarker in Parkinson's diagnosis and prognosis

Journal article
Authors L. Parnetti
Claudia Cicognola
P. Eusebi
D. Chiasserini
Published in Biomarkers in Medicine
Volume 10
Issue 1
Pages 35-49
ISSN 1752-0363
Publication year 2016
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 35-49
Language en
Keywords alpha-synuclein, cerebrospinal fluid biomarkers, cognitive impairment, disease progression, early, csf alpha-synuclein, multiple system atrophy, drug-naive patients, elevated levels, lewy bodies, monoclonal-antibodies, alzheimers-disease, dementia, disorders, mutation, Research & Experimental Medicine
Subject categories Psychiatry, Neuroscience


Since diagnosis of Parkinson's disease (PD) is mostly based on clinical criteria, it is almost impossible to formulate an early diagnosis, as well as a timely differential diagnosis versus other parkinsonisms. A great effort in searching reliable biomarkers both for early diagnosis and prognosis in PD is currently ongoing. Cerebrospinal fluid has been widely investigated as potential source for such biomarkers, with particular emphasis on -synuclein (-syn) species. We reviewed all the clinical studies carried out so far on cerebrospinal fluid quantification of -syn species in PD. Current evidence supports the value of total and oligomeric -syn in PD diagnosis and in the differential diagnosis of PD and other parkinsonisms. Conversely, the role of -syn species in PD prognosis remains unsatisfactory.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?